Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.

Seiler M, Yoshimi A, Darman R, Chan B, Keaney G, Thomas M, Agrawal AA, Caleb B, Csibi A, Sean E, Fekkes P, Karr C, Klimek V, Lai G, Lee L, Kumar P, Lee SC, Liu X, Mackenzie C, Meeske C, Mizui Y, Padron E, Park E, Pazolli E, Peng S, Prajapati S, Taylor J, Teng T, Wang J, Warmuth M, Yao H, Yu L, Zhu P, Abdel-Wahab O, Smith PG, Buonamici S.

Nat Med. 2018 May;24(4):497-504. doi: 10.1038/nm.4493. Epub 2018 Feb 19.

PMID:
29457796
2.

c-Myb and C/EBPβ regulate OPN and other senescence-associated secretory phenotype factors.

Flanagan KC, Alspach E, Pazolli E, Parajuli S, Ren Q, Arthur LL, Tapia R, Stewart SA.

Oncotarget. 2017 Dec 5;9(1):21-36. doi: 10.18632/oncotarget.22940. eCollection 2018 Jan 2.

3.

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.

Weir HM, Bradbury RH, Lawson M, Rabow AA, Buttar D, Callis RJ, Curwen JO, de Almeida C, Ballard P, Hulse M, Donald CS, Feron LJ, Karoutchi G, MacFaul P, Moss T, Norman RA, Pearson SE, Tonge M, Davies G, Walker GE, Wilson Z, Rowlinson R, Powell S, Sadler C, Richmond G, Ladd B, Pazolli E, Mazzola AM, D'Cruz C, De Savi C.

Cancer Res. 2016 Jun 1;76(11):3307-18. doi: 10.1158/0008-5472.CAN-15-2357. Epub 2016 Mar 28.

4.

p38MAPK plays a crucial role in stromal-mediated tumorigenesis.

Alspach E, Flanagan KC, Luo X, Ruhland MK, Huang H, Pazolli E, Donlin MJ, Marsh T, Piwnica-Worms D, Monahan J, Novack DV, McAllister SS, Stewart SA.

Cancer Discov. 2014 Jun;4(6):716-29. doi: 10.1158/2159-8290.CD-13-0743. Epub 2014 Mar 26.

5.

Chromatin remodeling underlies the senescence-associated secretory phenotype of tumor stromal fibroblasts that supports cancer progression.

Pazolli E, Alspach E, Milczarek A, Prior J, Piwnica-Worms D, Stewart SA.

Cancer Res. 2012 May 1;72(9):2251-61. doi: 10.1158/0008-5472.CAN-11-3386. Epub 2012 Mar 15.

6.

Osteopontin stimulates preneoplastic cellular proliferation through activation of the MAPK pathway.

Luo X, Ruhland MK, Pazolli E, Lind AC, Stewart SA.

Mol Cancer Res. 2011 Aug;9(8):1018-29. doi: 10.1158/1541-7786.MCR-10-0472. Epub 2011 Jun 14.

7.

Senescent stromal-derived osteopontin promotes preneoplastic cell growth.

Pazolli E, Luo X, Brehm S, Carbery K, Chung JJ, Prior JL, Doherty J, Demehri S, Salavaggione L, Piwnica-Worms D, Stewart SA.

Cancer Res. 2009 Feb 1;69(3):1230-9. doi: 10.1158/0008-5472.CAN-08-2970. Epub 2009 Jan 20.

8.

Senescence: the good the bad and the dysfunctional.

Pazolli E, Stewart SA.

Curr Opin Genet Dev. 2008 Feb;18(1):42-7. doi: 10.1016/j.gde.2007.12.002. Epub 2008 Feb 8. Review.

PMID:
18262406

Supplemental Content

Loading ...
Support Center